Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat by Smigielski, Lukasz et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Characterization and prediction of acute and sustained response to
psychedelic psilocybin in a mindfulness group retreat
Smigielski, Lukasz ; Kometer, Michael ; Scheidegger, Milan ; Krähenmann, Rainer ; Huber, Theo ;
Vollenweider, Franz X
Abstract: Meditation and psychedelics have played key roles in humankind’s search for self-transcendence
and personal change. However, neither their possible synergistic effects, nor related state and trait pre-
dictors have been experimentally studied. To elucidate these issues, we administered double-blind the
model psychedelic drug psilocybin (315 ￿g/kg PO) or placebo to meditators (n = 39) during a 5-day
mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively experienced
self-dissolution along the perception-hallucination continuum, without concomitant anxiety. Openness,
optimism, and emotional reappraisal were predictors of the acute response. Compared with placebo,
psilocybin enhanced post-intervention mindfulness and produced larger positive changes in psychoso-
cial functioning at a 4-month follow-up, which were corroborated by external ratings, and associated
with magnitude of acute self-dissolution experience. Meditation seems to enhance psilocybin’s positive
effects while counteracting possible dysphoric responses. These findings highlight the interactions be-
tween non-pharmacological and pharmacological factors, and the role of emotion/attention regulation
in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a
modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial
psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the
form of psychedelic-assisted applications.
DOI: https://doi.org/10.1038/s41598-019-50612-3
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://www.zora.uzh.ch/181563
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Smigielski, Lukasz; Kometer, Michael; Scheidegger, Milan; Krähenmann, Rainer; Huber, Theo; Vollen-
weider, Franz X (2019). Characterization and prediction of acute and sustained response to psychedelic
psilocybin in a mindfulness group retreat. Scientific Reports, 9:14914.
DOI: https://doi.org/10.1038/s41598-019-50612-3
1Scientific RepoRtS |         (2019) 9:14914  | https://doi.org/10.1038/s41598-019-50612-3
www.nature.com/scientificreports
characterization and prediction 
of acute and sustained response 
to psychedelic psilocybin in a 
mindfulness group retreat
Lukasz Smigielski, Michael Kometer, Milan Scheidegger, Rainer Krähenmann  , theo Huber 
& franz X. Vollenweider  
Meditation and psychedelics have played key roles in humankind’s search for self-transcendence 
and personal change. However, neither their possible synergistic effects, nor related state and trait 
predictors have been experimentally studied. to elucidate these issues, we administered double-
blind the model psychedelic drug psilocybin (315 μg/kg po) or placebo to meditators (n = 39) during 
a 5-day mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively 
experienced self-dissolution along the perception-hallucination continuum, without concomitant 
anxiety. openness, optimism, and emotional reappraisal were predictors of the acute response. 
compared with placebo, psilocybin enhanced post-intervention mindfulness and produced larger 
positive changes in psychosocial functioning at a 4-month follow-up, which were corroborated by 
external ratings, and associated with magnitude of acute self-dissolution experience. Meditation 
seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses. These 
findings highlight the interactions between non-pharmacological and pharmacological factors, and the 
role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well 
as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of 
mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions 
across numerous mental conditions in the form of psychedelic-assisted applications.
A burgeoning interest in the phenomenology and neurobiology of psychedelic drugs has grown in recent 
years, motivated by rising evidence of their therapeutic potential for some psychiatric disorders1,2. For exam-
ple, psilocybin reduced symptoms of therapy-resistant depression3 and depression and anxiety in terminal can-
cer patients4 after administration of just one or two doses. Psilocybin and other classic psychedelics are partial 
serotonin-2A-receptor agonists5 that may produce transient, profound changes in self-consciousness, experi-
enced as a dissolution of the ordinary sense of self and a breakdown of the perceived boundaries between the self 
and the world6. Empirical research has repeatedly reported that, in a supportive setting at medium-to-high doses 
(20–30 mg PO), psilocybin can trigger alterations of self-consciousness in association with feelings of bliss, unity, 
and insightfulness7–10. Such experiences have been referred to as at least partially overlapping occurrences of self/
ego dissolution11,12, self-loss13, states of selflessness14–16, mystical-type experiences17,18, or non-dual awareness19. 
Although the experiential quality of psilocybin-induced alterations resemble the states of self-transcendence 
reported by various traditions of Eastern descent20,21 and can occasionally occur during deep meditative prac-
tices22,23, there are no experimental data that support this assumption.
The intensity and form of psychedelic experience, indexed as mystical-type experience or self-dissolution 
effect, seem to mediate beneficial therapeutic outcomes24–26. Similarly, many meditation practices aim to reduce 
self-referential processing27,28 and achieve a temporary dissolution of self-boundaries15, which may lead to an 
enduring reduction of self-focus or ego-centricity14,29,30. Notably, meditation was found to alleviate symptoms of 
depression, anxiety, and stress and to promote lasting benevolent emotions and prosocial behavior30 in clinical 
and non-clinical populations31–33. Despite similarities between meditation- and psychedelic-induced temporary 
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alterations in the sense of self, neither the phenomenological similarities and differences of such multifaceted 
experiences nor the impact of additional putative modulatory factors have yet been systematically investi-
gated in a prospective study. The phenomenological differences between meditation- and psychedelic-induced 
self-dissolution may result in different long-term changes in psychosocial functions.
Many traditional meditative practices, and in particular mindfulness-based meditation such as Vipassana, 
Zen, and their secular forms34, aim at maintaining attention on the present moment with a non-judgmental, 
accepting stance toward the enfolding experiences15,35,36. This involves directing of attention, body awareness, 
and emotion regulation strategies to achieve an increased cognitive and emotional flexibility35–37 This, in turn, is 
thought to reduce self-centered psychological functioning15,30, which may culminate in states of selflessness15,38. 
Meditation experiences arise along a spectrum of meditation depth39 and are shaped by other factors, such as pre-
vious meditation experience, dispositional mindfulness, openness, and absorption40,41. However, profound states 
of selflessness during meditation occur rarely and mostly in long-term meditators22. In contrast, psilocybin can 
induce a state of self-dissolution at a relatively high rate (up to 60%), particularly at higher doses42,43, and along a 
perception-hallucination continuum with increasing emotional arousal.
Although the content and intensity of psychedelic experiences depend most critically on dosage44, the 
same dose can induce a pleasurable state of self-dissolution or, under certain circumstances, a more distressing 
response associated with thought disturbances, fear of losing control, anxiety, or panic45. The reactions to psyche-
delics and their subsequent interpretations are commonly shaped by the “set” (i.e., the subject’s expectation, per-
sonality traits, and current mood state) and “setting” (i.e., the physical and social environment in which the drug 
is taken)46–49. Considering the role of set and setting in study designs resulted in more positive subjective effects 
and fewer dysphoric reactions9,50 than in earlier experimental work that ignored these issues51,52. Thus, a better 
understanding of non-pharmacological variables for the outcome of the psychedelic experience seems crucial, in 
consideration of their suggested therapeutic potential.
Taken together, both meditation and psilocybin can promote a spectrum of altered states of consciousness that 
are modulated by additional dispositional (trait) and state factors. In this prospective, matched-group study, we 
quantified the effects of meditation alone and meditation combined with psilocybin in expert meditators partic-
ipating in a well-structured 5-day mindfulness-based meditation retreat. First, we explored whether state mind-
fulness and meditation depth increased across the retreat and whether psilocybin modulated these outcomes, in 
addition to direct pre-post trait-like mindfulness. Second, we compared the spectrum and extent of alterations of 
consciousness, indexed by the Altered States of Consciousness Rating Scale (5D-ASC), and mystical-type of expe-
rience, indexed by the Mysticism Scale (M-scale). Furthermore, we conducted a multiple regression analysis to 
explore whether a number of trait and state factors contributed to inter-individual differences in self-dissolution 
as measured by the 5D-ASC and M-Scale instruments. Specifically, we hypothesized that particular state and 
trait variables would influence self-dissolution, i.e., openness, extraversion, neuroticism53,54, absorption41,44, opti-
mism about life53, pre-experience with altered states53, mood and emotion regulation strategies36,44,53, trait and 
state mindfulness, and meditation depth the day before drug intake41. Additionally, we explored the possibility 
that the high cognitive and emotion regulation capacity of meditation experts36,55–58 would buffer possible dis-
tressing aspects of psychedelic experiences, such as negative emotions, anxiety, disorientation, and fear of loss 
of control and self-identity (colloquially known as a “bad trip”)59, which can arise with high doses of psilocy-
bin. Because both the extent of psilocybin-induced alterations of self-consciousness, as indexed by mystical-type 
experience4,26, and longer mindfulness-based meditation periods lead to persisting positive outcomes in healthy 
subjects31,60 and patient populations4,26,31,61, we explored whether the intensity of different sub-dimensions of 
the mystical-type experience predicted persisting changes in behavior and attitudes at a 4-month follow-up. 
We hypothesized that the combination of psilocybin and mindfulness meditation training would lead to larger 
changes than meditation alone.
Results
State mindfulness and meditation depth. During the 5-day retreat, participants practiced mindfulness 
meditation, which can be described as a temporary state of intentional self-regulation of attention to foster greater 
awareness of one’s sensations, emotions, and thoughts with a non-judgmental attitude. On day 4, participants 
received either a placebo or psilocybin in a double-blind manner.
Daily, at the end of the meditation session, participants rated the intensity of state mindfulness using the 
Toronto Mindfulness Scale (TMS). There was no significant interaction between group (placebo/psilocybin) and 
time (day 1 to 5) for total TMS score (ANOVA F(4,148) = 1.05, p = 0.38), and no significant main effect of group 
(F(1,148) = 0.41, p = 0.53), indicating that psilocybin did not significantly increase state mindfulness. However, 
there was a main effect of time (F(4,148) = 4.41, p < 0.01. Post-hoc tests showed that total TMS score increased 
from day 1 to day 5 (mean ± SEM: 29.61 ± 1.18; mean ± SEM: 32.42 ± 1.36; p < 0.05; Fig. 1A).
At the end of each meditation session, participants also rated meditation depth using the Meditation Depth 
Questionnaire (MEDEQ). There was a significant interaction between group (placebo/psilocybin) and time (day 
1 to day 5) for MEDEQ score (ANOVA F(4,148) = 4.69, p < 0.001). Post-hoc tests confirmed the hypothesized 
increase in mediation depth on day 4 in the psilocybin group was greater than that in the placebo group (p < 0.05; 
Fig. 1). We also found a significant main effect of time (F(4,148) = 14.44, p < 0.00001), but no main effect of 
group (F(1,37) = 2.44, p = 0.13). Post-hoc tests confirmed that MEDEQ score increased from day 1 to day 5 
(mean ± SEM: 63.0 ± 3.31 and 77.7 ± 3.74; p < 0.001, Fig. 1B).
trait mindfulness. Trait mindfulness was evaluated pre- and post-retreat, on day 0 and day 6, respectively, 
using the Freiburg Mindfulness Inventory (FMI, short form). There was a significant interaction between group 
(placebo/psilocybin) and time (pre-retreat, post-retreat) for FMI score (ANOVA F(1,37) = 4.14, p < 0.05) and a 
significant main effect of time (F(1,37) = 22.85, p < 0.0001. Post-hoc tests confirmed that FMI score was higher 
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post-retreat than pre-retreat (p < 0.001), and that post-retreat FMI score was higher in the psilocybin group than 
in the placebo group (p < 0.001; Fig. 2).
Subjective effects during psilocybin-assisted meditation. After psilocybin or placebo administra-
tion at 1030 h on day 4, participants engaged in their usual meditation practice, preserving complete silence. The 
psychological effects of psilocybin peak at about 60–90 min after drug intake, subside gradually, and are absent 
6 hours after drug intake62. To assess the effect of psilocybin on the subjective experience during the meditation 
session, participants completed the 5D-ASC and the M-scale. 5D-ASC is designed to quantify positive and nega-
tive forms of self/ego-dissolution, including perceptual alterations. The M-scale differentiates between extrover-
tive self-dissolution (framed by perception of unity and an outward merging with surroundings) and introvertive 
self-dissolution (framed by ego loss, spacelessness, and/or timelessness, denoting an inward unitary experience 
beyond time and space)63,64.
There was a significant interaction between group (placebo/psilocybin) and 5D-ASC main scales (Oceanic 
Boundlessness [OB], Visionary Restructuralization [VR], Vigilance Reduction [VIR], Anxious Ego Dissolution 
[AED], Acoustic Alterations [AA]) for 5D-ASC score (ANOVA F(4,148) = 36.27, p < 0.00001). Post-hoc tests 
indicated that the OB (p < 0.0001), VR (p < 0.0001), and VIR (p < 0.05) scores were higher in the psilocybin 
group than in the placebo group. By contrast, the groups did not differ on the AED and AA scales (SI Table 2).
A subsequent analysis of the subscale scores for the OB, VR, and AED core scales reveled a significant 
group × subscale interaction (F(10,37) = 13.14, p < 0.00001). Post-hoc tests indicated that scores for the 
OB-related subscales of unity, spiritual experience, blissfulness, insightfulness, and disembodiment were higher 
in the psilocybin group than in the placebo group (all p < 0.01). Similarly, scores for the VR-related subscales of 
Figure 1. (A) Levels of state mindfulness (Toronto Mindfulness Scale total score) and (B) meditation depth 
(Meditation Depth Questionnaire total score) over the course of the retreat. Data are means ± 1 SEM (standard 
error of the mean). The asterisk indicates a significant difference between psilocybin and placebo groups on day 
4, when the drug was administered (*p < 0.01). Both state mindfulness and meditation depth increased between 
day 1 and day 5 (mindfulness, mean ± SEM: 29.61 ± 1.18 and 32.42 ± 1.36 on day 1 and day 5, respectively, 
p < 0.05; meditation depth, mean ± SEM: 63.0 ± 3.31 and 77.7 ± 3.74 on day 1 and day 5, respectively, 
p < 0.001). The p-values have been adjusted for multiple comparisons within this analysis.
Figure 2. Trait mindfulness (Freiburg Mindfulness Inventory score) pre- and post-retreat. The score was 
significantly higher in the psilocybin group than in the placebo group on day 6, 2 days after psilocybin 
administration (*p < 0.001). When collapsed across the two groups (independent of drug treatment), trait 
mindfulness was significantly higher on day 6 (mean ± SEM: 46.2 ± 0.73) than on day 0 (mean ± SEM: 
43.3 ± 0.70). The p-values have been adjusted for multiple comparisons within this analysis.
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complex imagery, elementary imagery, audiovisual synesthesia, and changed meaning of percepts were higher in 
the psilocybin group than in the placebo group (all p < 0.01). By contrast, scores on the AED-related subscales of 
impaired control and cognition and anxiety did not differ between the two groups (p > 0.9; Fig. 3).
There was a significant interaction between group (placebo/psilocybin) and dimension (extrovertive mysti-
cism, introvertive mysticism, interpretation) for M-scale score (ANOVA F(2,74) = 14.81, p < 0.00001). Post-hoc 
tests indicated that, for all three dimensions, the score was higher in the psilocybin group than in the placebo 
group (all p < 0.01; SI Table 2). Extrovertive mysticism comprises the sub-dimensions unity of the world as one 
and inner subjectivity of all beings; introvertive mysticism comprises the sub-dimensions of ego loss, timeless-
ness/spacelessness, and ineffability of the experience; and interpretation comprises the sub-dimensions posi-
tive affect, sacredness, and noetic quality. Subsequent analysis indicated a significant interaction between group 
(placebo/psilocybin) and sub-dimension score (F(7,259) = 2.43, p < 0.05). Post-hoc tests indicated that, for all 
sub-dimensions, score was higher in the psilocybin group than in the placebo group (Fig. 4).
Prior to the retreat, participants used the M-scale to rate their strongest lifetime mystical experience. This was 
then compared with the mystical experience after drug administration during the retreat. There was a significant 
interaction between group (placebo/psilocybin) and time point (lifetime, retreat) on total M-scale score (ANOVA 
F(1,37) = 68.04, p < 0.00001), and a significant main effect of time point (F(1,37) = 49.53, p < 0.00001) and group 
(F(1,37) = 23.19, p < 0.0001; Fig. 5A). Individual M-scale scores revealed that 19 of 20 participants (95%) in the 
psilocybin group and 3 of 19 participants (16%) in the placebo group met the a priori criteria of 60% of scale 
Figure 3. Effects of psilocybin on the subscales of the Altered States of Consciousness Rating Scale (5D-ASC). 
Scores are expressed as percent of scale maximum. Error bars indicate ± 1 SEM (standard error of the mean). 
Asterisks indicate significant differences between psilocybin and placebo groups (***p < 0.0001, **p < 0.001, 
*p < 0.05). OB, Oceanic Boundlessness; AED, Anxious Ego Dissolution; VR, Visual Restructuralization. The  
p-values have been adjusted for multiple comparisons within this analysis.
Figure 4. Effect of psilocybin on sub-dimensions of the M-scale. Error bars are ± 1 SEM (standard error of the 
mean). Asterisks indicate significant differences between psilocybin and placebo groups (**p < 0.001). The  
p-values have been adjusted for multiple comparisons within this analysis.
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maximum for having had a “strong” mystical experience during the retreat (Fig. 5B). Figure 6 depicts in detail the 
score distribution of altered consciousness and perception for those participants.
The relations between score on each of the main dimensions of the 5D-ASC scale65 and each of the three 
dimensions of the M-scale66 were quantified using Pearson’s correlation coefficient. Inspection of the correlation 
matrix (SI Fig. 2) revealed that score on the OB dimension of the 5D-ASC scale correlated significantly with score 
on the extrovertive mysticism (r = 0.47), introvertive mysticism (r = 0.59), and interpretation (r = 0.59) dimen-
sions of the M-scale (all p < 0.01). No other correlations were significant.
predictors of acute subjective experience of meditation. Multiple regression analysis was used to 
explore if dispositional and state variables before drug intake predicted the acute alterations of consciousness (SI 
Table 4). Specifically, we tested whether age, personality traits (extraversion, neuroticism, and openness to expe-
rience), absorption capacity, optimistic attitude toward life, intensity of previous mystical-type experience, trait 
mindfulness (facets of presence and acceptance), emotion regulation strategies (suppression and reappraisal), 
state mindfulness, and meditation depth influenced score on the OB, AED, and VR main scales of the 5D-ASC 
questionnaire and on the extrovertive mysticism, introvertive mysticism, and interpretation dimensions of the 
M-scale. State mindfulness and meditation depth were assessed the day before drug intake, and all other predic-
tor variables were assessed prior to the start of the retreat. Psilocybin intake accounted for the largest proportion 
of the variance in all six outcome measures, with η2 ranging from 0.35 to 0.74. Optimistic attitude toward life 
accounted for a significant proportion of the variance in OB, VR, and the three core dimensions of mysticism 
(η2 = 0.16–0.25), and openness (η2 = 0.12–0.18) accounted for a significant proportion of the variance in OB and 
the three core dimensions of mysticism.
Furthermore, we explored the possibility that emotion regulation strategy and mindfulness practice may 
prevent anxiety and have a beneficial influence on the psychedelic experience. Indeed, reappraisal of emotions 
counteracted the intensity of AED (p < 0.0001, η2 = 0.21), and non-judgmental acceptance of thoughts and emo-
tions increased introvertive mysticism (p < 0.05 η2 = 0.14) and interpretation of mystical experience (p < 0.05 
η2 = 0.16). Finally, as expected meditation depth accounted for a significant proportion of the variance in OB 
(p < 0.0001, η2 = 0.38) and interpretation of mystical experience (p < 0.05 η2 = 0.13), notably both dimensions 
that depict positive emotions associated with self-dissolution.
Changes in behavior and attitudes at the 4-month follow-up. Four months after the retreat, partic-
ipants evaluated perceived changes in behavior and attitudes using the Life Changes Inventory, Revised (LCI-R). 
LCI-R score was significantly higher in the psilocybin group (mean ± SEM: 0.75 ± 0.09) than in the placebo group 
(mean ± SEM: 0.19 ± 0.05; F(1,37) = 23.41, p < 0.0001), indicating greater change in attitudes and behavior. There 
was a significant interaction between group (placebo/psilocybin) and LCI-R scale (F(8,296) = 9.28, p < 0.00001). 
Post-hoc tests indicated that scores on the LCI-R scales of appreciation for life, self-acceptance, quest for mean-
ing/sense of purpose, and appreciation of death were significantly higher in the psilocybin group than in the pla-
cebo group (all p < 0.01). There was also a trend toward a higher score on the concern for others and spirituality 
scales, and toward a lower score on the concern with worldly achievements scale (e.g., interest in material things, 
social status) (all p < 0.05–0.07; Fig. 7).
Each participant designated a closely related person with whom he/she had frequent contact since the retreat, 
to complete a third-person LCI-R with reference to the participant. Completed questionnaires were received 
from 39 data participants and 37 significant others. Two participants declared that there was no closely related 
person with whom they had frequent contact at that moment of their life. These community observer LCI-R 
ratings showed a similar, although less marked, overall pattern of changes with significantly higher scores on the 
self-acceptance and quest for meaning/sense of purpose scales in the psilocybin group than in the placebo group 
(all p < 0.01; SI Fig. 3).
Figure 5. (A) M-scale total score for lifetime experience versus acute drug experience for psilocybin and 
placebo groups. Error bars indicate ± 1 SEM (standard error of the mean). Asterisk indicates a significant 
difference between psilocybin and placebo groups (*p < 0.01). (B) M-scale total score for each participant. 
The a priori criterion of 60% of scale maximum for a “strong” mystical-type experience was met by 19 of 20 
participants (95%) in the psilocybin group and 3 of 19 participants (15.8%) in the placebo group.
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Meaningfulness of the study experience. At the follow-up, participants were asked how personally 
meaningful the study experience was. A large proportion of participants in the psilocybin group rated their expe-
rience as among either the top ten (50%) or five (35%) most meaningful experiences of their life, whereas the 
majority of participants in the placebo group rated their experience as meaningful as those experiences occurring 
once a month (37%), once a year (21%), or every 5 years (26%) (SI Table 3).
predictors of changes in attitude and behaviors. A multiple regression was used to test the hypothesis 
that certain features of the mystical-type experience would predict changes in attitudes and behaviors quantified 
by the LCI-R at the 4-month follow-up (SI Table 5). Psilocybin intake (p < 0.05, η2 = 0.15) and loss of ego bound-
aries (p < 0.01, η2 = 0.20) accounted for a significant amount of variance in total LCI-R score. Furthermore, psilo-
cybin intake (p < 0.001, η2 = 0.28) predicted score on the appreciation of death subscale. Sacredness accounted for 
a significant amount of variance in score on the appreciation of life scale (p < 0.00001, η2 = 0.48), and sacredness 
(p < 0.05, η2 = 0.11) together with ineffability (p < 0.01, η2 = 0.17) accounted for a significant amount of variance 
in score on the quest for meaning/sense of purpose scale. The experience of unity (p < 0.001, η2 = 0.32) accounted 
for a significant amount of variance in score on the self-acceptance scale.
Discussion
In the present study, we investigated the synergistic effects of psilocybin and mindfulness as well as related 
state and trait predictors in experienced meditators during a 5-day group retreat. Given the importance of 
set and setting in shaping reactions to psychedelics, we hypothesized that mindfulness training may deepen 
psychedelic-induced experiences. We also investigated the possibility that it may buffer the emotional overload 
and anxiety that can arise with self-dissolution effects67. We showed that state mindfulness and meditation depth 
gradually increased over the course of the retreat and that meditation depth was acutely increased by psilocy-
bin administration (Fig. 1). These findings demonstrate that during acute drug effects, experienced meditators 
were able to remain engaged in their usual meditation practice and that psilocybin has the capacity to deepen 
Figure 6. Comparison of subjective effects in participants from the psilocybin group (n = 19) with those in the 
placebo group (n = 3), who reached the a priori criteria for a “strong” mystical-type experience. Despite similar 
M-scale subdimensions (C), there were marked differences in various scale and subscale scores of altered states 
of consciousness (A,B), particularly in the domain of visual experiences.
Figure 7. Self-rated changes in attitude and behavior, evaluated using the Life Change Inventory, Revised, at 
a 4-month follow-up. Error bars indicate ± 1 SEM (standard error of the mean). Asterisks indicate significant 
differences between psilocybin and placebo groups (***p < 0.001, *p < 0.01, #p < 0.05–0.07). The p-values have 
been adjusted for multiple comparisons within this analysis.
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meditative states. Interestingly, dispositional mindfulness measured 1 day after the completion of the retreat was 
higher among participants who had received psilocybin than among those who had received placebo (Fig. 2). 
This finding aligns well with the observed increase in mindfulness capacity 24 hours after administration of the 
psychedelic N,N-dimethyltryptamine to healthy volunteers in the form ayahuasca68. Thus, the current findings 
corroborate the view that psychedelics may enhance mindfulness capacity68 and that dispositional mindfulness 
may change over time with practice, suggesting putative neuroplasticity-related modulations of this trait32,69,70.
The combination of psilocybin and meditation produced much stronger alterations of consciousness and 
a profound positively experienced self-dissolution (OB score) compared with meditation alone, and virtually 
without loss of cognitive control and anxiety (AED score), despite the relatively high dose of psilocybin that was 
used. However, the self-dissolution was accompanied by marked vivid imagery, ranging from elementary to com-
plex scenery hallucinations (VR score). A comparison of the 5D-ASC results in the psilocybin group with those 
obtained in healthy, non-meditating participants who had conducted a simple neuropsychological task under 
the same psilocybin dose44 revealed that meditation plus psilocybin resulted in substantially higher scores on the 
spiritual experience (66% vs. 22%), blissful state (86% vs. 48%), and feeling of unity (70% vs. 40%) subscales and 
lower scores on the AED and VIR scales than psilocybin alone, whereas the auditory and visual alterations did 
not differ44 (SI Fig. 1). These findings support our view that mindfulness-related trait and state capabilities may 
foster and positively shape the experiential quality of self-dissolution and buffer psilocybin-induced anxiety and 
vigilance deficits. Interestingly, a 1–2 month preparatory training in meditation and spiritual practice bolstered 
the positive effects on self-dissolution in healthy individuals, as tested with similar doses of psilocybin71.
Three participants in the placebo group met the a priori criteria for a strong mystical-type experience 
(Fig. 5B). Exploration of M-scale subscales indicated that the mystical-type experience reported by these pla-
cebo participants was very similar to that reported by the psilocybin participants. These findings provide the 
first experimental evidence and corroborate the view72 that meditation and psilocybin can occasion phenom-
enologically overlapping mystical-type experiences. However, there are also some notable differences between 
meditation- and psilocybin-induced alterations of consciousness. Whereas the mystical-type experiences in 
the placebo group arose virtually without anxiety, cognitive impairments, audiovisual synesthesia, or vigilance 
reduction, and with relative few elementary imageries, in the psilocybin group they were associated with vivid 
visual alterations, pronounced audiovisual synesthesia, moderate cognitive impairments, and vigilance reduction 
(Fig. 6A,B). Consistent with previous work, such experiences occur in deep meditation unpredictably and at a 
very low rate73,74, whereas psilocybin can occasion such positive mystical-type experiences in a supportive clinical 
setting at relatively high rates (≈60%)10,42,44,75. Psilocybin also produced more intense mystical-type experiences 
than placebo in the seminal “Good Friday Experiment”, where participants attended a Christian service in a group 
setting at Harvard University’s Marsh Chapel10. In light of these observations, we suggest that the retreat setting 
in the present study reassured, through the presence of others and social bonding, a safe and supportive environ-
ment that may have contributed to the positive outcomes of psilocybin-induced self-dissolution.
Our analysis of putative predictors of the acute psychedelic experience highlights that psilocybin was the 
most important determinant. This is consistent with a previous pooled analysis of psilocybin experiments44. In 
accordance with earlier studies46,76,77, we also found that the personality trait “openness” (expressing the level of 
permeability to novel experience) and optimism toward life contributed to the experience of OB, as well as the 
three core dimensions of mysticism. The significant correlation between OB and these three dimensions further 
supports this finding. Openness is composed of active imagination, attentiveness to inner feelings, intellectual 
curiosity, preference for variety, adventurousness, and aesthetic sensitivity, clustering together in one dimen-
sion78. This personality disposition not only predicted the positive outcome of psychedelic experiences53,60, but 
also correlated with the prevalence of spontaneously occurring mystical-type experiences79, and was associated 
with the meditation depth41. Consistent with previous work53, visionary experience was associated with the per-
sonality trait extroversion, but unlike earlier reports it was not correlated with the participant’s absorption capac-
ity44. In regard to the core components of mindfulness meditation practice, we found that reappraisal of emotions 
was negatively related to the AED dimension of altered states of consciousness and introvertive mysticism, which 
also refers to loss of ego functioning, whereas the mindfulness trait acceptance of thoughts and emotions corre-
lated positively with introvertive mysticism and the interpretation of mystical experience. Furthermore, medita-
tion depth assessed the day before drug administration substantially contributed to the OB dimension of altered 
states of consciousness and interpretation of mystical experience, both of which depict positive emotions asso-
ciated with self-dissolution. Relaxation the day before drug administration and age were predictors of positive 
self-dissolution in a previous study53. In light of these observations, it is conceivable that mindfulness training 
may help to buffer the emotional distress and anxiety that may arise with the ego dissolution state. This may 
happen by promoting reappraisals, more flexible selection of interpretation of the experience, and redirection 
of emotional load. A better understanding of non-pharmacological variables could help stratify individuals and 
better predict specific responses to classical psychedelics.
The follow-up results highlight that changes in behaviors were significantly higher in the psilocybin group 
than in the placebo group for appreciation of life, self-acceptance, quest for meaning and sense of purpose, and 
appreciation of death (Fig. 7). The pattern of changes was similar although less pronounced than that obtained 
from an external observer (SI Fig. 3). This adds to the literature reporting transformational processes following 
psychedelic experiences. Comparable enduring positive changes in attitude and behavior after one or two doses 
of psilocybin have been reported to persist at least 14 months80 or more81. Interestingly, although our participants 
were well-functioning individuals who scored high in life satisfaction at baseline, it appears that they could still 
greatly benefit from the psilocybin-facilitated experience.
Remarkably, despite the long engagement of our study participants in contemplative practices, the psilocy-
bin experience was valued equivalent to their strongest lifetime mystical-type experience (Fig. 5A). Moreover, 
most participants in the psilocybin group attributed a high personal meaning to the psilocybin experience: 37% 
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considered it one of the five, and 47% one of the ten most meaningful life experiences. However, this finding 
is somewhat less pronounced than that of a recent study in non-meditating psilocybin subjects42,80. A possible 
explanation for this difference is that we administered a lower dose of psilocybin and the long-term medita-
tion practice may support the cultivation of enduring happiness and well-being. Additionally, being open to 
moment-to-moment experiences, without the aim to judge them and create any attachments, may have contrib-
uted to these comparably less pronounced effects on personal meaning.
Our regression analysis of predictors of the long-term behavioral changes showed that the extent of 
self-dissolution and the drug administration substantially contributed to the global change in attitude and behav-
ior. Moreover, the experience of unity as an index of reduced self-other boundaries and oneness with the sur-
rounding predicted self-acceptance. This temporary loss of the ordinary ego/self and self-boundaries appears 
to diminish self-referential processing or ego-centricity and thus to foster an altered perspective toward oneself, 
others, and the environment. This interpretation is supported by recent findings demonstrating that psilocybin 
modulates neuronal activity in brain networks that mediate a sense of self8,82. Furthermore, the sense of sacred-
ness contributed to the change in appreciation of life, and sacredness and ineffability contributed to the change in 
quest for meaning/sense of purpose, across both groups independent of drug condition. These findings support 
the view that spiritual experiences, including sense of sacredness and ineffability, contribute to psychological 
well-being83–85, and act through meaning-making mechanisms86,87. In line with a recent large survey reporting 
that peak psychedelic experiences were linked to reduced fear of death72, we found that psilocybin alone predicted 
the change in appreciation of death. This is also consistent with recent studies demonstrating that the extent of 
psilocybin-occasioned mystical-type experience mediated the reduction of existential anxiety and depression in 
terminal cancer patients4,26.
The perceptible effects of psychoactive drugs pose a methodological challenge in maintaining the integrity of 
blinding procedures. Therefore, a major limitation of this study was the use of an inert placebo and the possible 
recognition of the active and non-active conditions by participants. However, this choice was motivated by the 
objective to quantify the meditation-specific parameters without additional confounding factors, i.e., with respect 
to the inactive placebo. Nevertheless, we reduced the element of expectancy by including solely psychedelic-naïve 
volunteers (≈2/3 of the sample) and those with limited previous exposure to consciousness-altering drugs (≈1/3 
of the sample). Furthermore, we obscured the experimental conditions (i.e., placebo versus psilocybin) through 
a highly structured silent retreat that limited interpersonal exchange within the group setting, with instructions 
emphasizing individual practice. Even though it remains possible that the observed effects reflect some expec-
tancy, we argue based on previous results from our group and other researchers that they are likely attributable to 
the unique psychoactive profile of psilocybin.
In addition to the overall positive outcome of psilocybin administration found in this study, a few results 
compel further discussion. At the dose tested, psilocybin produced no adverse events (including physical dis-
comfort, disorientation, severe anxiety, panic, or psychotic-like reactions) neither acutely during the trial session 
nor post-acutely during the retreat. Two participants reported in the postacute psychiatric investigation that they 
felt transiently emotionally overwhelmed during the peak effect of the drug, but did not value this as negative. 
No adverse events or persistent negative effects were reported at the 4-month follow-up. The low ratings on the 
5D-ASC scale for “anxiety” (mean score, 3%; min–max range, 0–10%) are in accordance with and even smaller 
than those reported by previous studies, suggesting that even during peak effects psilocybin is well tolerated 
and rarely produces profound or psychotic anxiety in a controlled clinical setting in healthy human subjects6. 
However, it should be said that challenging psychological experiences may still occur as acute and durable effects 
of both meditation practice and psychedelic ingestion, including psychological distress or disorientation88, psy-
chotic episodes, panic attacks, depersonalization, or asociality89. The incidence of adverse effects can be reduced 
by proper medical and psychological screening, a reassuring setting, and supervision.
The present study demonstrated that the combination of psilocybin and mindfulness training increased 
the incidence and intensity of alterations of consciousness characterized by profound states of self-dissolution 
and virtually no anxiety. Personality traits and core components of mindfulness-based meditation shaped the 
different facets of selflessness. The psilocybin-induced dissolution of self, either due to a perception of unity 
of all things and/or ego loss, mediated beneficial enduring changes in psychosocial functioning. The effect of 
psilocybin on meditation depth and trait mindfulness may increase the effective positive impact of meditation 
retreats on psychological outcome. Both meditation depth and higher levels of mindfulness have been linked to 
a wide range of well-being and mental health markers31,90. The present results also suggest that the combination 
of mindfulness training and psychedelic-assisted intervention may offer potential for the further development 
of psychedelic-assisted applications to improve well-being and health in both therapeutic and non-therapeutic 
settings
Methods
participants. Participants were 39 expert Buddhist meditation practitioners. The study was advertised as an 
experiment investigating the effect of psilocybin on mindfulness practice embedded in a 5-day meditation retreat. 
Participants were recruited through flyers in local meditation communities and advertisements in professional 
Buddhist magazines devoted to meditation. In total, 202 individuals submitted written applications, of which 79 
potentially eligible persons were further screened for criteria for participation over the phone. In the next screen-
ing stage, 54 were invited to the clinic for a medical check-up and psychological evaluation, and 40 were finally 
qualified for the study. Participants were healthy according to medical history, physical examination, routine 
blood analysis, electrocardiography, and urine tests for drug abuse and pregnancy. The study was approved by the 
Cantonal Ethics Committee of Zurich, Switzerland. Written informed consent was obtained from every partici-
pant before enrollment, and the study was performed according to the Declaration of Helsinki. See Supplemental 
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Information for further information on screening procedures and participation criteria and SI Table 1 for detailed 
sample characteristics.
Substance and dosing. The study was conducted using a double-blind, placebo-controlled, 
between-subject design. Psilocybin (315 μg/kg of body weight; body weight of subjects, 69.07 ± 12.07 kg; absolute 
dose, 21.76 ± 3.8 mg) and placebo (lactose) were administered in identical gelatin capsules. The high dose of 
psilocybin was chosen with reference to previous studies, in which a similar dose induced a significant change in 
consciousness without producing deep thought disturbances or complete loss of self-control6. The use of psilocy-
bin according to the study protocol was authorized by the Swiss Federal Office for Public Health, Department of 
Pharmacology and Narcotics, Bern.
Study procedures and setting. The 40 participants were randomly allocated to one of two groups (pla-
cebo, psilocybin) matched for age, gender, mindfulness level, meditation experience (quantified as lifetime hours 
of meditation practice), and retreat experience (quantified as number of attended retreats). One participant with-
drew after the matching procedure. Two retreats at different times and following the same procedures with 16 
(8 placebo/8 psilocybin) and 23 (11 placebo/12 psilocybin) subjects were conducted. During the retreat, the 
participants engaged in daily, structured meditation sessions in which they sat upright facing a wall, kept their 
eyes half open, and engaged in meditation practice. On day 4, participants in each group received either placebo 
or psilocybin, administered in a double-blind manner.
The retreats were held in a meditation center where, for 5 days, the participants lived and practiced meditation 
under the guidance of an experienced Zen teacher. All individuals followed a structured meditative discipline 
known in the Zen tradition as sesshin. The daily schedule consisted of a 15 hour highly structured program (from 
0600 to 2100 h) including typical elements of mindfulness-based Zen practice: 8 × 30 min sitting meditation 
(zazen), 5 × 10 min indoor and 2 × 30 min outdoor walking meditation (kinhin), 75 min of mindful physical work 
(samu), interleaved with recitations, short rest breaks, and meals. The participants were instructed to observe 
silence during the whole retreat. Psilocybin and placebo were administered on the fourth day at 1030 h following 
a slightly adapted schedule containing additional musical elements and short relaxation periods. Thus, the retreat 
was conceptually divided into three phases: preparation (days 1–3), psilocybin/placebo administration (proper 
experience on day 4), and post-experience integration (day 5).
Trait mindfulness was evaluated the day preceding the retreat and the day following the retreat. State mind-
fulness and meditation depth were evaluated at the end of each day of the retreat (2100 h). Altered states of con-
sciousness and mysticism were evaluated 360 min after drug administration.
Perceived changes in behaviors and attitudes were evaluated at a follow-up, 4 months after the retreat. At this 
time point, participants also answered the question “How personally meaningful was the experience made during 
the study?” (1 - no more than everyday experiences; 2 - similar to meaningful experiences that occur on average once 
or more a week; 3 - once a month; 4 - once a year; 5 - once every 5 years; 6 - among the ten most meaningful experi-
ences of my life; 7 - among the five most meaningful experiences of my life; 8 - the single most meaningful experience 
of my life)9. Additionally, each participant designated a closely related person with whom he/she had frequent 
contact since the retreat, such as a family member or close friend, who would likely notice changes in the partic-
ipant’s behavior and attitudes. This individual was asked to provide a third-person evaluation of changes (if any) 
in the participant’s behavior and attitudes.
Baseline measures. At baseline, the following information was collected to characterize and enable match-
ing of the study sample: socio-demographic data, meditation tradition, hours of formal meditation practice, 
history of drug use, Multiple Choice Vocabulary Test91 (verbal fluency intelligence), FMI92 long form (disposi-
tional/trait mindfulness, completed with reference to the preceding 2 months), Satisfaction with Life Scale93, and 
Symptom Checklist-90-Revised94. The last measure was used as a screening inventory to detect clinical symptoms 
and indicators of psychological distress and was completed with reference to the last month.
Personality, absorption (propensity to become absorbed in experiences), dispositional optimism and pessi-
mism, emotion regulation strategies, and the occurrence of primary mystical experiences over the course of a 
lifetime were also evaluated at baseline and considered in the analysis as possible predictors. Personality was eval-
uated using the NEO Five-Factor Inventory95. This is a concise 60-item measure of five basic personality dimen-
sions: extraversion, agreeableness, conscientiousness, neuroticism, and openness to experience. The propensity to 
become absorbed in experiences was evaluated using the Tellegen Absorption Scale96, which consists of 34 items. 
Dispositional optimism and pessimism were evaluated using the Life Orientation Test, Revised97, which consists 
of ten items. Emotion regulation strategies were evaluated using the Emotion Regulation Questionnaire98, which, 
by means of ten items, evaluates the habitual use of two emotion regulation strategies: cognitive reappraisal and 
expressive suppression. The occurrence of primary mystical experiences over the course of a lifetime was evalu-
ated using the M-scale (lifetime version)99. This 32-item questionnaire derives from Stace’s common criteria of 
mysticism100 and has been extensively used in the field of psychology of religion with well-documented reliability, 
validity, and cross-cultural generalizability101,102. The total score, ranging from 32 (least mystical) to 160 (most 
mystical), as well as three core dimensions and subdimensions were used for analysis103.
outcome measures. Trait mindfulness. Trait mindfulness was evaluated the day preceding the retreat and 
the day following the retreat using the FMI short form104. The FMI short form is a 14-item reliable instrument 
assessing the construct of mindfulness closely following Buddhist conceptualization. Mindfulness was treated as a 
one-dimensional construct, but separate factors of presence and acceptance were also used to refine the predictor 
analysis. The FMI was completed with reference to the previous 5 days.
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State mindfulness. State mindfulness was evaluated on each day of the retreat using the TMS105, a 13-item meas-
ure particularly well-suited to evaluate the level of mindfulness in those who actively practice it. It conceptualizes 
the construct as an intentional, reflective style of introspection or self-observation. The TMS was completed at the 
end of the evening meditation session (2100 h) with reference to the meditation practice of the corresponding day.
Meditation depth. Meditation depth was evaluated on each day of the retreat using the MEDEQ39, which is a 
30-item questionnaire designed to capture five aspects of meditation experience: hindrances (e.g., being restless), 
relaxation (e.g., feeling calm), concentration (e.g., being attentive and detached from emotions and thoughts), 
transpersonal qualities (e.g., feeling connected, bliss, and grace), and non-dual qualities (e.g., complete rest of 
thoughts and emotions, experiencing unity of all things). The global MEDEQ score was used for analysis. The 
instrument was completed at the end of the evening meditation session (2100 h) with reference to the meditation 
practice of the corresponding day.
Altered states of consciousness. Alteration of consciousness was evaluated 360 min after drug administration 
using the 5D-ASC65. This measure comprises 94 visual-analogue items, each rated as a percentage score of a 
maximum scale value, and was used to quantify the experiential effects of the drug, compared with the pla-
cebo. The instrument is a well-validated tool for measuring etiology-independent altered states of conscious-
ness and has been frequently used in previous studies with psilocybin. The global score, the five original 
scales, and the 11 empirically derived subscales106 were quantified. The five original scales are as follows: [OB] 
Oceanic Boundlessness (derealization and depersonalization, positive affect, altered time perception), [AED] 
Anxious Ego Dissolution (personal disintegration, loss of self-control, anxiety, thought disturbances), [VR] 
Visual Restructuralization (visual hallucinations and imagery, synesthesia, changed meaning of percepts), [AA] 
Auditory Alterations (auditory illusions and hallucinations), and [VIR] Vigilance Reduction (changes in vigilance 
and alertness). This instrument was completed with reference to drug/placebo experience.
Mystical-type experiences. Mystical-type experiences were evaluated around 360 min after drug administra-
tion using the M-scale63. This comprises three culture-independent core dimensions depicting eight facets of 
mystical-type experiences: extrovertive mysticism, comprising the sub-dimensions unity of the world as one 
and inner subjectivity of all beings; introvertive mysticism comprising the sub-dimensions ego loss, timeless-
ness/spacelessness, and ineffability of the experience; and interpretation, comprising the sub-dimensions positive 
affect, sacredness, and noetic quality. The interpretation dimension reflects a first interpretation of the mystical 
experience. The scale was found to be sensitive to the effects of psilocybin9,42. The following measures were used 
for analysis: total score, introvertive mysticism score (characterized by an inward-facing ego loss, time and space-
lessness, and ineffability), extrovertive mysticism score (relating to the experience of unity of all things and inner 
subjectivity), interpretation score (referring to a positive mood, sacredness, and noetic quality)103, and score on 
each of the eight original sub-dimensions to allow for comparisons with earlier studies. This instrument was 
completed with reference to drug/placebo experience.
Changes in behavior and attitudes. Changes in behavior and attitudes associated with a possibly transformative 
event were evaluated at the follow-up time point, 4 months after the retreat, using the LCI-R107. The LCI-R was 
originally used in the context of near-death experiences and adapted for the purpose of this study. The instrument 
consists of 50 items, each rated on a five-point Likert scale ranging from −2 (strongly decreased) to +2 (strongly 
increased). The items indicate the change in nine clusters (scales) and combine to create one total change score. 
Two versions of the instrument were used: a self-report version was completed by participants, and a third-person 
version was completed by the significant others. Both versions were completed with reference to the 4-month 
period following the retreat. All questionnaires were anonymized before analysis.
Statistical analysis. Independent sample t-tests and Pearson chi square tests were used to compare contin-
uous and categorical variables, respectively, between the two groups (psilocybin, placebo) to evaluate matching.
A two-way repeated measures ANOVA with group (psilocybin, placebo) as a between-subject factor and 
dimension or subscale (when appropriate) as a within-subject factor was used to compare the score from the 
5D-ASC rating, M-scale, and LCI-R (main scales and subscales of the 5D-ASC, dimensions and subdimensions 
of the M-scale, and their global/total scores). A two-way repeated measures ANOVA with group (psilocybin, 
placebo) as a between-subject factor and scale version (lifetime, acute) as a within-subject factor was used to 
compare the strongest mystical experience across lifespan with the acute psilocybin-induced experience in the 
study. A two-way repeated measures ANOVA with group (psilocybin, placebo) as a between-subject factor and 
time (days 1–5) as a within-subject factor was used to assess TMS score and MEDEQ score across the retreat. 
A two-way repeated measures ANOVA with group (psilocybin, placebo) as a between-subject factor and time 
(pre-retreat, post-retreat) as a within-subject factor was used to assess FMI score. When significant effects were 
found, post-hoc pairwise comparisons were performed and p- values were adjusted using Tukey’s HSD test.
Pearson’s correlation coefficient was used to quantify the relation between score on each of the main scales of 
the 5D-ASC and each of the core dimensions of the M-scale, with p-values reported after correction for multiple 
comparisons (SI Fig. 2).
Backward-removal regression analyses were run to evaluate predictors of acute effects (global 5D-ASC score, 
total M-scale score, score on the OB, AED, and VR scales of the 5D-ASC, and score on the extrovertive mysticism, 
introvertive mysticism, and interpretation dimensions of the M-scale) and follow-up effects (change in attitudes 
and behaviors). Regression analyses for acute effects included the following predictors: age, neuroticism, extra-
version, openness, absorption, optimism, lifetime mystical experience, presence and acceptance facets of mind-
fulness, suppression and reappraisal types of emotion regulation, mindfulness as state, and meditation depth on 
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the day of pharmacological intervention, as well as group (placebo/psilocybin). Regression analyses for follow-up 
effects included the following predictors: score on each of the eight sub-dimensions of the M-scale and group 
(placebo/psilocybin). The criterion for significance was set at p < 0.05.
Data Availability
Data is available upon personal request.
References
 1. Nichols, D. E., Johnson, M. W. & Nichols, C. D. Psychedelics as Medicines: An Emerging New Paradigm. Clin Pharmacol Ther 101, 
209–219, https://doi.org/10.1002/cpt.557 (2017).
 2. Vollenweider, F. X. & Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat 
Rev Neurosci 11, 642–651, https://doi.org/10.1038/nrn2884 (2010).
 3. Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 
Lancet Psychiatry 3, 619–627, https://doi.org/10.1016/S2215-0366(16)30065-7 (2016).
 4. Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with 
l i fe-threatening cancer :  a  randomized control led tr ia l .  J  Psychopharmacol  30 ,  1165–1180,  https://doi.
org/10.1177/0269881116675512 (2016).
 5. Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like 
psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897–3902 (1998).
 6. Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy 
humans: a pooled analysis of experimental studies. Journal of Psychopharmacology 25, 1434–1452 (2011).
 7. Leuner, H. Halluzinogene. Psychische Grenzzustände in Forschung und Therapie. 1 edn, 1–458 (Hans Huber, 1981).
 8. Lebedev, A. V. et al. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping 
36, 3137–3153, https://doi.org/10.1002/hbm.22833 (2015).
 9. Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and 
sustained personal meaning and spiritual significance. Psychopharmacology 187, 268–283, https://doi.org/10.1007/s00213-006-
0457-5 (2006).
 10. Pahnke, W. N. Drugs & Mysticism: An Analysis of the Relationship between Psychedelic Drugs and Mystical Consciousness 
Divinity. Harvard University, Cambridge MA, 315 (1963).
 11. Scharfetter, C. EPP (Ego-Psychopathology). 1 edn, (Psychiatric University Hospital Zürich, Research Department, 1990).
 12. Nour, M. M., Evans, L., Nutt, D. & Carhart-Harris, R. L. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution 
Inventory (EDI). Front Hum Neurosci 10, 269, https://doi.org/10.3389/fnhum.2016.00269 (2016).
 13. Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M. & Berkovich-Ohana, A. Psychedelics, meditation, and self-
consciousness. Frontiers in psychology 9 (2018).
 14. Dambrun, M. When the dissolution of perceived body boundaries elicits happiness: The effect of selflessness induced by a body 
scan meditation. Consciousness and cognition 46, 89–98 (2016).
 15. Dambrun, M., Ricard, M. & Self-Centeredness and Selflessness: A Theory of Self-Based Psychological Functioning and Its 
Consequences for Happiness. Rev Gen Psychol 15, 138–157, https://doi.org/10.1037/a0023059 (2011).
 16. Ataria, Y., Dor-Ziderman, Y. & Berkovich-Ohana, A. How does it feel to lack a sense of boundaries? A case study of a long-term 
mindfulness meditator. Consciousness and Cognition 37, 133–147 (2015).
 17. Hood, R. W., Hill, P. C. & Spilka, B. The psychology of religion: An empirical approach. (Guilford Press, 2009).
 18. Hood, R. W. Jr. & Francis, L. J. Mystical experience: Conceptualizations, measurement, and correlates. (2013).
 19. Josipovic, Z. Duality and nonduality in meditation research. Conscious Cogn 19, 1119–1121, discussion 1122–1113, https://doi.
org/10.1016/j.concog.2010.03.016 (2010).
 20. Nichols, D. E. & Chemel, B. R. The neuropharmacology of religious experience: Hallucinogens and the experience of the divine. 
Where God and science meet: How brain and evolutionary studies alter our understanding of religion 3, 1–33 (2006).
 21. Grinspoon, L. & Bakalar, J. B. Psychedelic drugs reconsidered. (Basic Books, 1979).
 22. Austin, J. H. Zen-Brain Reflections: Reviewing Recent Developments in Meditation and States of Consciousness. (MIT Press, 2006).
 23. Austin, J. H. Zen and the brain: Toward an understanding of meditation and consciousness. (The MIT Press, 1999).
 24. Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of 
Psilocybin for Treatment-Resistant Depression. Front Pharmacol 8, 974, https://doi.org/10.3389/fphar.2017.00974 (2017).
 25. Garcia-Romeu, A., Griffiths, R. R. & Johnson, M. W. Psilocybin-occasioned mystical experiences in the treatment of tobacco 
addiction. Curr Drug Abuse Rev 7, 157–164 (2014).
 26. Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-
threatening cancer: A randomized double-blind trial. J Psychopharmacol 30, 1181–1197, https://doi.org/10.1177/0269881116675513 
(2016).
 27. Vago, D. R. & Silbersweig, D. A. Self-awareness, self-regulation, and self-transcendence (S-ART): a framework for understanding 
the neurobiological mechanisms of mindfulness. Front Hum Neurosci 6, 296, https://doi.org/10.3389/fnhum.2012.00296 (2012).
 28. Dahl, C. J., Lutz, A. & Davidson, R. J. Reconstructing and deconstructing the self: cognitive mechanisms in meditation practice. 
Trends Cogn Sci 19, 515–523, https://doi.org/10.1016/j.tics.2015.07.001 (2015).
 29. Baer, R. A. Self-focused attention and mechanisms of change in mindfulness-based treatment. Cogn Behav Ther 38(Suppl 1), 
15–20, https://doi.org/10.1080/16506070902980703 (2009).
 30. Dambrun, M. Self-centeredness and selflessness: happiness correlates and mediating psychological processes. PeerJ 5, e3306, 
https://doi.org/10.7717/peerj.3306 (2017).
 31. Khoury, B., Knauper, B., Schlosser, M., Carriere, K. & Chiesa, A. Effectiveness of traditional meditation retreats: A systematic 
review and meta-analysis. J Psychosom Res 92, 16–25, https://doi.org/10.1016/j.jpsychores.2016.11.006 (2017).
 32. Khoury, B. et al. Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev 33, 763–771, https://doi.
org/10.1016/j.cpr.2013.05.005 (2013).
 33. Grossman, P., Niemann, L., Schmidt, S. & Walach, H. Mindfulness-based stress reduction and health benefits: A meta-analysis. 
Journal of psychosomatic research 57, 35–43 (2004).
 34. Kabat‐Zinn, J. Mindfulness‐based interventions in context: past, present, and future. Clinical psychology: Science and practice 10, 
144–156 (2003).
 35. Malinowski, P. Neural mechanisms of attentional control in mindfulness meditation. Front Neurosci 7, 8, https://doi.org/10.3389/
fnins.2013.00008 (2013).
 36. Holzel, B. K. et al. How Does Mindfulness Meditation Work? Proposing Mechanisms of Action From a Conceptual and Neural 
Perspective. Perspect Psychol Sci 6, 537–559, https://doi.org/10.1177/1745691611419671 (2011).
 37. Fisher, N. R., Mead, B. R., Lattimore, P. & Malinowski, P. Dispositional mindfulness and reward motivated eating: The role of 
emotion regulation and mental habit. Appetite 118, 41–48, https://doi.org/10.1016/j.appet.2017.07.019 (2017).
 38. Dor-Ziderman, Y., Berkovich-Ohana, A., Glicksohn, J. & Goldstein, A. Mindfulness-induced selflessness: a MEG 
neurophenomenological study. Front Hum Neurosci 7, 582, https://doi.org/10.3389/fnhum.2013.00582 (2013).
1 2Scientific RepoRtS |         (2019) 9:14914  | https://doi.org/10.1038/s41598-019-50612-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
 39. Piron, H. The meditation depth index (MEDI) and the meditation depth questionnaire (MEDEQ). Journal for Meditation and 
Meditation Research 1, 69–92 (2001).
 40. Tang, Y. Y., Holzel, B. K. & Posner, M. I. Traits and states in mindfulness meditation. Nat Rev Neurosci 17, 59, https://doi.
org/10.1038/nrn.2015.7 (2016).
 41. Hölzel, B. K. & U. O., Relationship between mediation depth, absorption, mediation practice, and mindfullness: A laten variable 
approach. The Journal of Transpersonal Psychology 38, 20 (2006).
 42. Griffiths, R. R. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 
Psychopharmacology (Berl) 218, 649–665, https://doi.org/10.1007/s00213-011-2358-5 (2011).
 43. Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy 
humans: a pooled analysis of experimental studies. J. Psychopharmacol 25, 1434–1452 (2011).
 44. Studerus, E., Gamma, A., Kometer, M. & Vollenweider, F. X. Prediction of psilocybin response in healthy volunteers. PLoS One 7, 
e30800, https://doi.org/10.1371/journal.pone.0030800 (2012).
 45. van Amsterdam, J., Opperhuizen, A. & van den Brink, W. Harm potential of magic mushroom use: a review. Regul Toxicol 
Pharmacol 59, 423–429, https://doi.org/10.1016/j.yrtph.2011.01.006 (2011).
 46. Preller, K. H. & Vollenweider, F. X. Phenomenology, structure, and dynamic of psychedelic states (2016).
 47. Hartogsohn, I. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on 
psychopharmacology. J Psychopharmacol 30, 1259–1267, https://doi.org/10.1177/0269881116677852 (2016).
 48. Langlitz, N. The persistence of the subjective in neuropsychopharmacology: observations of contemporary hallucinogen research. 
Hist Human Sci 23, 37–57 (2010).
 49. Faillace, L. A. & Szara, S. Hallucinogenic drugs: influence of mental set and setting. Diseases of the nervous system (1968).
 50. Leary, T., Litwin, G. & Metzner, R. Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137, 
561–573 (1963).
 51. Malitz, S., Esecover, H., Wilkens, B. & Hoch, P. H. Some observations on psilocybin, a new hallucinogen, in volunteer subjects. 
Compr Psychiatry 1, 8–17 (1960).
 52. Hollister, L. E. C. biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130, 42–52 (1961).
 53. Dittrich, A. In 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) Ch. 8, 101–118 
(Parthenon Publishing, 1994).
 54. Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Neuroticism is associated with challenging experiences with psilocybin mushrooms. 
Pers Individ Dif 117, 155–160, https://doi.org/10.1016/j.paid.2017.06.004 (2017).
 55. Lutz, A., Slagter, H. A., Dunne, J. D. & Davidson, R. J. Attention regulation and monitoring in meditation. Trends Cogn Sci 12, 
163–169, https://doi.org/10.1016/j.tics.2008.01.005 (2008).
 56. Lutz, J. et al. Mindfulness and emotion regulation—an fMRI study. Social cognitive and affective neuroscience 9, 776–785 (2013).
 57. Kral, T. R. et al. Impact of short-and long-term mindfulness meditation training on amygdala reactivity to emotional stimuli. 
NeuroImage 181, 301–313 (2018).
 58. Chiesa, A., Serretti, A. & Jakobsen, J. C. Mindfulness: Top–down or bottom–up emotion regulation strategy? Clinical psychology 
review 33, 82–96 (2013).
 59. Strassman, R. J. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172, 577–595 (1984).
 60. MacLean, K. A., Johnson, M. W. & Griffiths, R. R. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases 
in the personality domain of openness. J Psychopharmacol 25, 1453–1461, https://doi.org/10.1177/0269881111420188 (2011).
 61. Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 
Psychopharmacology (Berl), https://doi.org/10.1007/s00213-017-4771-x (2017).
 62. Hasler, F., Grimberg, U., Benz, M. A., Huber, T. & Vollenweider, F. X. Acute psychological and physiological effects of psilocybin in 
healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology 172, 145–156 (2004).
 63. Hood, R. W. The construction and preliminary validation of a measure of reported mystical experience. Journal for the scientific 
study of religion, 29–41 (1975).
 64. Hood, R. W. Theory and Methods in the Psychological Study of Mysticism. Int J Psychol Relig 23, 294–306, https://doi.org/10.1080
/10508619.2013.795803 (2013).
 65. Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 
31(Suppl 2), 80–84, https://doi.org/10.1055/s-2007-979351 (1998).
 66. Rümmele, W. & Gnirss, F. Untersuchungen mit Psilocybin, einer psychotropen Substanz aus Psilocybe Mexicana. Schweiz Arch 
Neurol Neurochir Psychiatr 87, 365–385 (1961).
 67. Preller, K. H. & Vollenweider, F. X. In Behavioral Neurobiology of Hallucinogens, Entactogens, and Psychotomimetics Current Topics 
in Behavioral Neurosciences (eds Halberstadt, A. L., Nichols, D. E. & Vollenweider, F. X.) 360–389 (Springer, 2016).
 68. Soler, J. et al. Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. 
Psychopharmacology 233, 823–829, https://doi.org/10.1007/s00213-015-4162-0 (2016).
 69. Tang, Y. Y., Hölzel, B. K. & Posner, M. I. The neuroscience of mindfulness meditation. Nat Rev Neurosci 16, 213–225, https://doi.
org/10.1038/nrn3916 (2015).
 70. Ly, C. et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep 23, 3170–3182, https://doi.org/10.1016/j.
celrep.2018.05.022 (2018).
 71. Griffiths, R. R. et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices 
produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J 
Psychopharmacol 32, 49–69, https://doi.org/10.1177/0269881117731279 (2018).
 72. Yaden, D. B. et al. Of roots and fruits: a comparison of psychedelic and nonpsychedelic mystical experiences. Journal of Humanistic 
Psychology 57, 338–353 (2017).
 73. Austin, J. H. Zen and the Brain: Toward an Understanding of Meditation and Consciousness. (The MIT Press, 1998).
 74. Paloutzian, R. & Park, C. Directions for the future of psychology of religion and spirituality: research advances in methodology and 
meaning systems. Handbook of the Psychology of Religion and Spirituality, 651–665 (2013).
 75. Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and 
sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187, 268–283 (2006).
 76. Rinkel, M., DiMascio, A., Robey, A. & Atwell, C. Personality patterns and reaction to psilocybine. Neuro-psychopharmacology 2, 
56–85 (1961).
 77. Fischer, R., Marks, P. A., Hill, R. M. & Rockey, M. A. Personality structure as the main determinant of drug induced (model) 
psychoses. Nature 218, 296–298 (1968).
 78. McCrae, R. R. & John, O. P. An introduction to the five‐factor model and its applications. Journal of personality 60, 175–215 (1992).
 79. Majeski, R. A. The relationship of transpersonal self-transcendence, extraversion, openness to experience, and psychological well-being 
in mature adult female meditators and non-meditators.(women), ProQuest Information & Learning (1999).
 80. Griffiths, R. R., Richards, W., Johnson, M., McCann, U. & Jesse, R. Mystical-type experiences occasioned by psilocybin mediate the 
attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22, 621–632, https://doi.
org/10.1177/0269881108094300 (2008).
 81. Doblin, R. Pahnke’s Good Friday experiment: a long-term followup and methodological critique. Journal of Transpersonal 
Psychology 23, 1–28 (1991).
13Scientific RepoRtS |         (2019) 9:14914  | https://doi.org/10.1038/s41598-019-50612-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
 82. Preller, K. H. et al. The 5-HT2A/1A Agonist Psilocybin Enhances Empathy and Reduces Social Pain in Healthy Volunteers. 
Biological Psychiatry 77, 134S–135S (2015).
 83. Byrd, K. R., Lear, D. & Schwenka, S. Mysticism as a predictor of subjective well-being. The International Journal for the Psychology 
of Religion 10, 259–269 (2000).
 84. Goldstein, E. D. Sacred moments: Implications on well‐being and stress. Journal of clinical psychology 63, 1001–1019 (2007).
 85. Koenig, H. G. Religion, spirituality, and health: The research and clinical implications. ISRN psychiatry 2012 (2012).
 86. Park, C. L. Religiousness/spirituality and health: A meaning systems perspective. Journal of behavioral medicine 30, 319–328 
(2007).
 87. Seitz, R. J. & Angel, H.-F. Psychology of religion and spirituality: meaning-making and processes of believing. Religion, Brain & 
Behavior 5, 139–147 (2015).
 88. Carbonaro, T. M. et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive 
and negative consequences. Journal of Psychopharmacology 30, 1268–1278 (2016).
 89. Van Gordon, W., Shonin, E. & Garcia-Campayo, J. Are there adverse effects associated with mindfulness? Australian & New 
Zealand Journal of Psychiatry 51, 977–979 (2017).
 90. Piron, H. Meditation depth, mental health, and personal development. Journal for Meditation and Meditation Research 3, 45–58 
(2003).
 91. Lehrl, S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B. (Spitta, 1999).
 92. Buchheld, N., Grossman, P. & Walach, H. Measuring mindfulness in insight meditation (Vipassana) and meditation-based 
psychotherapy: The development of the Freiburg Mindfulness Inventory (FMI). Journal for Meditation and Meditation Research 1, 
11–34 (2001).
 93. Diener, E. D., Emmons, R. A., Larsen, R. J. & Griffin, S. The satisfaction with life scale. Journal of personality assessment 49, 71–75 
(1985).
 94. Derogatis, L. SCL-90-R: Symptom Checklist-90-R: administration, scoring, and procedures manual. NCS Pearson (1996).
 95. Costa, P. T. Jr. & McCrae, R. R. Domains and facets: Hierarchical personality assessment using the Revised NEO Personality 
Inventory. Journal of personality assessment 64, 21–50 (1995).
 96. Tellegen, A. & Atkinson, G. Openness to absorbing and self-altering experiences (“ absorption”), a trait related to hypnotic 
susceptibility. Journal of abnormal psychology 83, 268 (1974).
 97. Scheier, M. F., Carver, C. S. & Bridges, M. W. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-
esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol 67, 1063–1078 (1994).
 98. Gross, J. J. & John, O. P. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-
being. Journal of personality and social psychology 85, 348 (2003).
 99. Hood, R. W. Jr. The construction and preliminary validation of a measure of reported mystical experience. Journal for the scientific 
study of religion, 29–41 (1975).
 100. Stace, W. (Philadelphia, Lippincott, 1960).
 101. Hill, P. C. & Hood, R. W. Measures of religiosity. (Religious Education Press, 1999).
 102. Spilka, B., Hood, R. W., Hunsberger, B. & Gorsuch, R. The psychology of religion: An empirical approach. (Guilford Press, 2003).
 103. Hood, R. W., Morris, R. J. & Watson, P. J. Further factor analysis of Hood’s Mysticism Scale. Psychological Reports 73, 1176–1178 
(1993).
 104. Walach, H., Buchheld, N., Buttenmüller, V., Kleinknecht, N. & Schmidt, S. Measuring mindfulness—the Freiburg mindfulness 
inventory (FMI). Personality and Individual Differences 40, 1543–1555 (2006).
 105. Lau, M. A. et al. The Toronto Mindfulness Scale: development and validation. J Clin Psychol 62, 1445–1467, https://doi.org/10.1002/
jclp.20326 (2006).
 106. Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). 
PLoS One 5, e12412, https://doi.org/10.1371/journal.pone.0012412 (2010).
 107. Greyson, B. & Ring, K. The life changes inventory–revised. Journal of Near-Death Studies 23, 41–54 (2004).
Acknowledgements
The authors thank Vanja Palmers, Zen teacher, for guiding the retreat, Peter Gasser, Anke Röskamp, Juraj and 
Sonja Styk, Karim Tissira, and David Andel for psychological and medical supervision of the retreat, and Sara 
Romer, Anja Seidl, Brigitte Wicki, Niklas Bürgi, and Rahel Nicolet for organizational support and assistance with 
data collection. This study was supported by the Swiss Neuromatrix Foundation (2014-0101).
Author Contributions
L.S. and M.K. designed the experiments. L.S., M.K., M.S., R.K., and T.H. performed the experiment. L.S. and 
F.X.V. analyzed the data and wrote the manuscript. All authors further edited the paper and approved the final 
version of this manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50612-3.
Competing Interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
  Supplementary Information for 
 
Characterization and prediction of acute and sustained response to 
psychedelic psilocybin in a mindfulness group retreat 
 
Lukasz Smigielski
1*
, Michael Kometer
1
, Milan Scheidegger
1
, Rainer Krähenmann
1
, Theo 
Huber
1
, Franz X. Vollenweider
1
 
 
1
Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy 
and Psychosomatics, Psychiatric Hospital, University of Zurich, Lenggstrasse 31, CH-8032 
Zurich, Switzerland 
 
*
Corresponding author: lukasz.smigielski@uzh.ch or lu.smigielski@gmail.com 
 
Content: 
Supplementary Text 
Tables 1-5 
Figures 1-3 
References 
 
 
 
 
 
 2 
Supplementary Information 
 
SI Table 1. Study population demographics, screening, and baseline measures 
 
  
     Placebo group 
            n = 19 
     
  Psilocybin group 
          n = 20 
 
    χ2  
 
p-value 
     
 
 
   N     %     N    %   
       
Sex       0.041  0.84 
  Male    11 57.9%    12 60.0%   
  Female     8 42.1%     8 40.0%   
Meditation tradition
a
       0.005
 
  0.95 
   Zen    16 84.2%    17 85.0%   
   Vipassana      3 15.8%     3 15.0%   
Previous drug experience
b
       
   None    10 52.6%    11  55.0%   
   ≤3 times, over 20 years ago     6 31.6%     4 20.0%   
   ≤3 times in the last 20 years     3 15.8%     5 25.0%   
      
    M  SE    M  SE    t
 
 p-value 
      
Age (years) 50.47 2.15 52.80 1.55 -0.88  0.383 
Education (years) 15.42 0.81 14.75 1.04 0.50  0.618 
Multiple Choice Vocabulary Test score
 c
  124.53 3.66 119.55 3.17 1.03  0.309 
Meditation experience       
  Hours of meditation
d
 4826.3 1339.8 6155.0 1803.0 -0.59  0.561 
  Number of retreats
e
 30.58 11.16 31.60 6.60 -0.08  0.937 
Freiburg Mindfulness Inventory (long form) score 88.89 1.90 92.50 2.04 -1.29  0.205 
Tellegen Absorption Scale score 68.21 5.30 75.45 3.55 -1.15  0.259 
NEO Five Factor Inventory score       
  Neuroticism   2 0.18 2.02 0.18 -0.09  0.924 
  Extraversion 3.22 0.17 3.07 0.17  0.63  0.527 
  Openness 4.3 0.11 4.25 0.13  0.31  0.761 
Life Orientation Test, Revised, score       
  Optimism 8.37 0.43 8.70 0.54 -0.47 0.638 
Meaning in Life Questionnaire score       
 3 
  Presence of meaning 26.53 1.26 27.05 1.31  0.29 0.775 
  Search for meaning 22.95 1.78 22.00 1.95 -0.36 0.722 
Emotion Regulation Questionnaire score       
  Suppression 13.68 0.99 13.65 0.93 -0.11 0.909 
  Reappraisal 31.58 0.98 31.75 1.12 -0.21 0.831 
Satisfaction with Life Scale score 25.16 0.91 26.25 1.26  0.69 0.491 
Freiburg Mindfulness Inventory (short form) score       
  Presence 19.16 0.49 19.35 0.57 -0.25 0.800 
  Acceptance 23.68 0.63 24.55 0.71 -0.91 0.367 
Lifetime ASC
f
 experience score (M-scale) 133.74 4.67 130.65 4.71  0.47 0.645 
Symptom Checklist-90-R (Global Severity Index)   0.33 0.04 0.27 0.05 -0.91 0.371 
 
M, mean; SE, standard error. t-values are from two-tailed independent sample t-tests for continuous variables 
and Pearson chi square test
 
for categorical variables; df = 37.
  
a
The only practiced or primary meditation tradition by participants.
   
b
Previous experience with consciousness altering drugs (psilocybin, lysergic acid diethylamide (LSD), 
mescaline, N,N-dimethyltryptamine (DMT), 3,4-methylenedioxymethamphetamine (MDMA), ketamine, and 
their derivates; cannabis, and alcohol were not considered).  
c
Measure of verbal fluency intelligence.
 
d
Total lifetime hours of formal meditation practice.  
e
Number of meditation retreats lasting at least 3 consecutive days (lifetime).  
f
Altered states of consciousness.
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Participants: screening details 
The health screening included the Symptom Checklist-90-Revised
1
, clinical 
anamnesis, somatic examination, electrocardiography, and detailed blood analysis. The 
structured Mini-International Neuropsychiatric Interview
2
 was used to exclude potential axis I 
and II psychiatric disorders according to the DSM-IV diagnostic guidelines. Exclusion criteria 
were poor knowledge of German language, major somatic or neurological disorder, present or 
antecedent psychiatric disorder in the participant or a first-degree relative, alcohol or drug 
dependence or abuse, current or recent use of medication or drug affecting the nervous 
system, and pregnancy. Main inclusion criteria were age between 20 and 65 years, no or very 
limited exposure to hallucinogenic drugs, minimum of 500 hours of lifetime formal 
meditation practice, Mahayana (Zen) or Theravada (Vipassana) Buddhism as primary 
meditation background, familiarity with longer periods of meditation in a retreat setting, and 
for Vipassana practitioners, a previous exposure to Zen-specific elements of meditative 
discipline. The last criteria ensured that participants would likely comply with the study 
specific procedures and adapt to physical and emotional rigors of the demanding daily 
practice. Both Zen and Vipassana practitioners were included due to their resemblance: both 
are deeply rooted in Buddhist tradition, and both are founded on the cultivation of 
mindfulness (in Pāli, sati)3 and have developed a repertoire of similar mental techniques 
including sitting and walking meditation practices.  
To detect a possible recent use of psychoactive substances, a urine test sensitive to 
amphetamines, benzodiazepines, tetrahydrocannabinol, cocaine, methadone, and opiate 
metabolites was performed on the first day of the study. For female participants, an additional 
urine check was conducted to exclude pregnancy. No test was positive for any of these 
markers. Forty individuals who met the predefined criteria were enrolled in the study. One 
person withdrew after randomization, and the remaining 39 took part in the experiment. All 
volunteers were informed about the study procedures and potential risks related to the use of 
psilocybin. Board and lodging for subjects during the study was free of charge, and study-
related travel costs were compensated. No additional monetary incentive was offered for 
participation.  
 
Details on randomisation, blinding, and drug administration 
Psilocybin was obtained through the Swiss Federal Office of Health, Department of Narcotics 
and prepared as gelatin capsules containing 1 and 5 mg of psilocybin by the Hospital 
Pharmacy of the Canton of Lucerne, which also prepared the respective placebo capsules of 
 5 
identical appearance (containing 1 and 5 mg of mannitol, respectively). The study applied a 
stratified randomization procedure after all 40 participants had been enrolled in the study. 
First, subjects were balanced according five strata categories in the following order: age, 
gender, trait mindfulness level, meditation experience, and retreat experience. Second, 
subjects were then randomly allocated to the two groups. Third, blinded bottles containing 
weight-specific dosages (rounded to two decimals places) were prepared by combining 5 and 
1 mg psilocybin or placebo capsules, respectively, all of identical appearance. The 
randomization and blinding were performed by an authorized research physician in 
collaboration with the University Hospital Pharmacy who had no further role in the study. All 
collected raw data were anonymized and transferred to our licensed Clinical Trial Unit, where 
they were coded into a GCP-based electronic data base protected by double-login control by a 
research assistant who had no further role in the subsequent statistical data analysis. Data 
transfer and data quality were guaranteed in a second step by the clinical study manager. For 
the subsequent statistical analysis, data were initially coded as group 1 and 2, and finally un-
blinded for interpretation of the results.  
  
 6 
SI Table 2. Subjective effects measured using the Altered States of Consciousness Rating Scale (5D-
ASC) and Mysticism Scale (M-scale) 
 
Questionnaire 
 
 
Scale / dimension 
 
Placebo  
 
 
Psilocybin  
  Mean (SE) Range Mean (SE) Range 
5D-ASC      
 Oceanic Boundlessness 10.94 (3.44) 0–47.81 62.95 (4.82)*** 10.41–97.04 
 Visionary Restructuralization 5.40 (2.21) 0–31.78 49.96 (4.61)*** 5.94–81.67 
 Anxious Ego Dissolution 1.74 (0.53) 0–9.53 7.59 (1.36)      0.95–24.90 
 Auditory Alterations 1.65 (0.59) 0–9.44 10.88 (2.09) 0.88–33.44 
 Vigilance Reduction 4.24 (1.38) 0–19.83 18.57 (2.77)* 6.42–52.75 
M-scale  
Extrovertive 
 
25.37 (3.38) 
 
12–60 
 
52.65 (1.78)** 
 
32–60 
  
Introvertive 
 
15.42 (1.84) 
 
8–40 
 
30.10 (1.53)** 
 
12–40 
  
Interpretation 
 
29.84 (2.89) 
 
16–60 
 
52.90 (1.39)** 
 
40–60 
 
 
SE, standard error. Asterisks indicate significant differences between psilocybin and placebo groups (*** = 
p < 0.0001, ** = p < 0.001, * = p < 0.05). The p-values have been adjusted for multiple comparisons within 
this analysis. 
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Explorative comparison of setting effects 
To further explore the putative synergistic effects of psilocybin and meditation, the 
score on each of the 11 5D-ASC subscales was compared between the psilocybin group in the 
present study (n = 20) and participants from a previous study on the effect of psilocybin in 
non-meditators who completed four simple neuropsychological tasks in a laboratory setting (n 
= 20)
4
. An explorative analysis of covariance with group (psilocybin retreat/psilocybin 
laboratory) as a between-subjects factor, 5D-ASC subscale score as a within-subject factor, 
and age as a covariate revealed a significant group × subscale interaction (F(10,350) = 2.09, p 
< 0.05) with no main effect of age (F(35,1) = 0.42, p = 0.52). Post-hoc tests indicated that the 
scores for the unity, spiritual experiences, and blissfulness were higher for the psilocybin 
retreat group than for the psilocybin laboratory group, while the score for the audio-visual 
synesthesia was lower for the first group than for the second group (SI Fig. 1).  
 
 
 
SI Figure 1. Radar chart comparing the score for each subscale of altered states of 
consciousness in the psilocybin retreat group (n = 20) and non-meditators who took the same 
dose of psilocybin (n = 20) in laboratory setting from our database
4
 (* = p < 0.05, ** = p < 
0.01, *** p < 0.001). For further comparison, the scores of the three placebo subjects who met 
the a priori criteria for a strong mystical-type experience are also shown. The p-values have 
been adjusted for multiple comparisons within this analysis. 
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SI Figure 2. Correlations between scores on each dimension of the Altered Stated of 
Consciousness Rating Scale (5D-ASC) and M-scale. Score on the Oceanic Boundlessness 
(OB) scale of the 5D-ASC correlated significantly with the score on the extrovertive 
mysticism (r = 0.47), introvertive mysticism (r = 0.59), and interpretation (r = 0.59) 
dimensions of the M-scale (all p < 0.01). No other correlations were significant. VR, Visual 
Restructuralization; AED, Anxious Ego Dissolution; AA, Auditory Alterations; VIR, 
Vigilance Reduction. 
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SI Figure 3. Changes in attitude and behavior, evaluated by a significant other using the Life 
Changes Inventory, Revised, at a 4-month follow-up. Bars are means and error bars indicate 
SEM (standard error of the mean). Asterisks indicate significant differences between 
psilocybin and placebo groups: * = p < 0.01. The p-values have been adjusted for multiple 
comparisons within this analysis. 
 
 
 
 
 
 
 
 
 
 
  
L
C
I-
R
 s
c
a
le
 s
c
o
re
 (
o
b
s
e
rv
e
r)
 
 10 
SI Table 3. Meaningfulness of study experience 
 
How personally meaningful was the 
experience made during the study? 
 
   
      Placebo group        Psilocybin group 
        
      n = 19       %              n = 20       % 
1. No more than everyday experiences                                                                       1         5.3%              0           0% 
2. Similar to meaningful experiences that occur on average once or more a week          1         5.3%              0           0% 
3. Similar to meaningful experiences that occur on average once or more a month        7        36.8%             0           0% 
4. Similar to meaningful experiences that occur on average once a year                         4        21.1%             1           5% 
5. Similar to meaningful experiences that occur on average once every 5 years             5        26.3%             2           10% 
6. Among the ten most meaningful experiences of my life                                                 1        5.3%             10           50% 
7. Among the five most meaningful experiences of my life                                                0          0%                7          35% 
8. The single most meaningful experience of my life                                                         0           0%                0            0% 
 
Note: percentage (%) and number (n) of participants rating the question on personal meaning of the overall 
retreat experience.  
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SI Table 4. Predictors of psychological responses evaluated using main scales of the 5D-ASC and main dimensions of the M-scale  
 
 
              Oceanic Boundlessness                         Anxious Ego Dissolution                 Visual Restructuralization                Extrovertive Mysticism                    Introvertive Mysticism                      Interpretation 
 
 
     Whole model R
2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
  0.82 5,33 36.54 0.00001  0.41 2,36 14.27 0.0001  0.75 3,35 39.35 0.00001  0.69 4,34 22.63 0.00001  0.65 6,32 12.92 0.00001  0.80 8,30 20.16 0.00001  
     Multiple Regression  
      backward removal 
                              
  β df F p < η
2 β df F p < η2 β df F p < η2 β df F p < η2 β df F p < η2 β df F P < η2 
 Predictor                               
 Age                          
0.26 1 10.76 0.01 0.26 
 Neuroticism 
                              
 Extraversion 
          
0.25 1 9.13 0.01 0.21 
               
 Openness 0.19 1 7.12 0.01 0.18 
          
0.21 1 4.84 0.05 0.12 0.22 1 4.82 0.05 0.13 0.20 1 6.62 0.05 0.18 
 Absorption 0.18 1 4.41 0.05 0.12 
                         
 Optimism 0.24 1 10.71 0.01 0.25 
     
0.27 1 10.27 0.01 0.23 0.24 1 6.65 0.01 0.16 0.27 1 7.25 0.01 0.18 0.26 1 11.17 0.01 0.27 
 Lifetime mysticism 
               
0.31 1 11.56 0.01 0.25 0.29 1 7.84 0.01 0.20 0.22 1 5.94 0.05 0.17 
 Mindfulness: Presence 
                         
-0.19 1 4.19 0.05 0.12 
 Mindfulness: Acceptance 
                    
0.27 1 5.00 0.05 0.14 0.22 1 5.85 0.05 0.16 
 Emotion Regulation: S  
                              
 Emotion Regulation: R 
     
-0.39 1 9.58 0.01 0.21 
          
-0.30 1 6.29 0.05 0.16 
     
 State Mindfulness*  
                              
 Meditation Depth*  0.42 1 20.27 0.0001 0.38 
                    
0.21 1 4.58 0.05 0.13 
 Group placebo-psilocybin 0.68 1 84.18 0.00001 0.72 0.55 1 19.46 0.0001 0.35 0.81 1 98.73 0.00001 0.74 0.78 1 74.74 0.00001 0.69 0.69 1 48.76 0.00001 0.60 0.63 1 55.27 0.00001 0.65 
 
N        Note: df, degrees of freedom; R2ajd, R2 adjusted; η2, partial eta squared; *, drug session; R, Reappraisal; S, Suppression. 
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SI Table 5. M-scale dimensions as predictors of behavioral changes evaluated using the Life Changes Inventory, Revised 
 
 
                                     LCI-R total score                                    LCI-R Appreciation for life                    LCI-R Self-acceptance                            LCI-R Quest for meaning                        Appreciation of death 
 
Note: df, degree of freedom; R2ajd, R2 adjusted; η2, partial eta squared. 
 
 
 
Whole model R
2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
R2adj df F p < 
 
 
0.48 2,36 18.70 0.00001 
 
0.47 1,37 34.45 0.00001 
 
0.30 1,37 17.64 0.001 
 
0.49 2,36 19.58 0.00001 
 
0.26 1,37 14.64 0.001 
 
Multiple Regression  
backward removal 
                         
 
β df F p < η2 β df F p < η2 β df F p < η2 β df F p < η2 β df F p < η2 
Predictors 
(M-Scale dimensions)                          
 
Inner subjectivity                         
 
Unity 
          
0.57 1 17.64 0.001 0.32 
         
 
Time/Spacelessness 
                        
 
Ego loss 0.43 1 8.97 0.01 0.20 
                   
 
Ineffability 
               
0.44 1 7.48 0.01 0.17 
    
 
Positive affect 
                        
 
Sacredness 
     
0.69 1 34.45 0.00001  0.48 
     
0.34 1 4.49 0.05 0.11 
    
 
Noetic quality 
                        
 
Group placebo-psilocybin 0.37 1 6.44 0.05 0.15 
               
0.53 1 14.64 0.001      0.28 
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